Literature DB >> 18826295

Modeling binding modes of alpha7 nicotinic acetylcholine receptor with ligands: the roles of Gln117 and other residues of the receptor in agonist binding.

Xiaoqin Huang1, Fang Zheng, Clare Stokes, Roger L Papke, Chang-Guo Zhan.   

Abstract

Extensive molecular docking, molecular dynamics simulations, and binding free energy calculations have been performed to understand how alpha7-specific agonists of nicotinic acetylcholine receptor (nAChR), including AR-R17779 (1), GTS-21 (4), and 4-OH-GTS-21 (5), interact with the alpha7 receptor, leading to important new insights into the receptor-agonist binding. In particular, the cationic head of 4 and 5 has favorable hydrogen bonding and cation-pi interactions with residue Trp149. The computational results have also led us to better understand the roles of Gln117 and other residues in the receptor binding with agonists. The computational predictions are supported by data obtained from wet experimental tests. The new insights into the binding and structure-activity relationship obtained from this study should be valuable for future rational design of more potent and selective agonists of the alpha7 receptor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18826295      PMCID: PMC3077129          DOI: 10.1021/jm800607u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

1.  Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors.

Authors:  Vladimir V Uteshev; Edwin M Meyer; Roger L Papke
Journal:  J Neurophysiol       Date:  2002-12-04       Impact factor: 2.714

2.  Amyloid beta(1-42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors.

Authors:  Francesca Grassi; Eleonora Palma; Raffaella Tonini; Mascia Amici; Marc Ballivet; Fabrizio Eusebi
Journal:  J Physiol       Date:  2003-01-17       Impact factor: 5.182

3.  Agonist activation and alpha-bungarotoxin inhibition of wild type and mutant alpha7 nicotinic acetylcholine receptors.

Authors:  F E Kempsill; P J Covernton; P J Whiting; J G Connolly
Journal:  Eur J Pharmacol       Date:  1999-11-03       Impact factor: 4.432

4.  (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor.

Authors:  G Mullen; J Napier; M Balestra; T DeCory; G Hale; J Macor; R Mack; J Loch; E Wu; A Kover; P Verhoest; A Sampognaro; E Phillips; Y Zhu; R Murray; R Griffith; J Blosser; D Gurley; A Machulskis; J Zongrone; A Rosen; J Gordon
Journal:  J Med Chem       Date:  2000-11-02       Impact factor: 7.446

Review 5.  The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21).

Authors:  W R Kem
Journal:  Behav Brain Res       Date:  2000-08       Impact factor: 3.332

6.  Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase.

Authors:  Chang-Guo Zhan; Fang Zheng; Donald W Landry
Journal:  J Am Chem Soc       Date:  2003-03-05       Impact factor: 15.419

7.  Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.

Authors:  William R Kem; Vladimir M Mahnir; Laszlo Prokai; Roger L Papke; Xuefang Cao; Susan LeFrancois; Kristin Wildeboer; Katalin Prokai-Tatrai; Julia Porter-Papke; Ferenc Soti
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

8.  Agonist-induced conformational changes in the extracellular domain of alpha 7 nicotinic acetylcholine receptors.

Authors:  Lisa K Lyford; Adrian D Sproul; Donnie Eddins; James T McLaughlin; Robert L Rosenberg
Journal:  Mol Pharmacol       Date:  2003-09       Impact factor: 4.436

9.  Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.

Authors:  Roger L Papke; Julia K Porter Papke
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

10.  Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures.

Authors:  Patrick H N Celie; Sarah E van Rossum-Fikkert; Willem J van Dijk; Katjusa Brejc; August B Smit; Titia K Sixma
Journal:  Neuron       Date:  2004-03-25       Impact factor: 17.173

View more
  13 in total

1.  Computational modeling study of human nicotinic acetylcholine receptor for developing new drugs in the treatment of alcoholism.

Authors:  Zeng-Jian Hu; Li Bai; Yousef Tizabi; William Southerland
Journal:  Interdiscip Sci       Date:  2009-11-14       Impact factor: 2.233

Review 2.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

3.  Cocaine esterase-cocaine binding process and the free energy profiles by molecular dynamics and potential of mean force simulations.

Authors:  Xiaoqin Huang; Xinyun Zhao; Fang Zheng; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2012-03-02       Impact factor: 2.991

4.  Design, synthesis, and biological activity of 5'-phenyl-1,2,5,6-tetrahydro-3,3'-bipyridine analogues as potential antagonists of nicotinic acetylcholine receptors.

Authors:  Yafei Jin; Xiaoqin Huang; Roger L Papke; Emily M Jutkiewicz; Hollis D Showalter; Chang-Guo Zhan
Journal:  Bioorg Med Chem Lett       Date:  2017-08-14       Impact factor: 2.823

5.  First-Principles Determination of Molecular Conformations of Indolizidine (-)-235B' in Solution.

Authors:  Fang Zheng; Linda P Dwoskin; Peter A Crooks; Chang-Guo Zhan
Journal:  Theor Chem Acc       Date:  2009-10-01       Impact factor: 1.702

6.  QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum.

Authors:  Fang Zheng; Matthew J McConnell; Chang-Guo Zhan; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2009-05-08       Impact factor: 3.641

Review 7.  The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis.

Authors:  Marjolein A van Maanen; Margriet J Vervoordeldonk; Paul P Tak
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

8.  Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands.

Authors:  Jing-Fang Yang; Alexander H Williams; Narsimha R Penthala; Paul L Prather; Peter A Crooks; Chang-Guo Zhan
Journal:  ACS Chem Neurosci       Date:  2020-09-30       Impact factor: 4.418

9.  Identification of a negative allosteric site on human α4β2 and α3β4 neuronal nicotinic acetylcholine receptors.

Authors:  Ryan E Pavlovicz; Brandon J Henderson; Andrew B Bonnell; R Thomas Boyd; Dennis B McKay; Chenglong Li
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

Review 10.  In Silico Modeling of the α7 Nicotinic Acetylcholine Receptor: New Pharmacological Challenges Associated with Multiple Modes of Signaling.

Authors:  Alican Gulsevin; Roger L Papke; Nicole Horenstein
Journal:  Mini Rev Med Chem       Date:  2020       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.